{
  "docId": "019de074-1527-7308-955d-4c9eab2bbacb",
  "docSlug": "e812f3c221148b99b15c4527dea8f94b",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 15,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/14",
  "deckHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb",
  "deckJsonHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json",
  "deckAnchorHref": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.113,
        "y": 0.225
      },
      "kind": "list",
      "text": "The benefits of targeting FcRn and lowering total IgG levels were demonstrated by clinically and statistically significant improvements in platelet counts compared with placebo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "059af3cf-7156-4800-8581-b5bffc667102",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.113,
        "y": 0.615
      },
      "kind": "list",
      "text": "The results of the study support both weekly and every-other-week administration, allowing for adjustments based on platelet counts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "063fba4d-920c-42d7-a2cb-a602fa29932d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.113,
        "y": 0.78
      },
      "kind": "list",
      "text": "Over 90% of participants who completed ADVANCE IV enrolled in the open-label extension (ADVANCE+; NCT04225156)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f1bce4c-c4f5-40ce-b3de-2f3a7635fc61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.113,
        "y": 0.45
      },
      "kind": "list",
      "text": "Efgartigimod was well-tolerated and most adverse events were mild to moderate with no new safety signals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "710c505c-44a4-421f-af38-9a9ad70a4b40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.101,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "FcRn = neonatal Fc receptor; IgG = immunoglobulin G; IV = intravenous.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "098987ed-5d51-4613-a473-27b82c73bb34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.55,
        "x": 0.098,
        "y": 0.085
      },
      "kind": "title",
      "text": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e4f2f96-57aa-403f-95f8-7994b8ba24a8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 14,
      "beatId": "3200b2c0-e740-44b5-8fc8-5bd350f76fb3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions (slide 14).",
      "position": 5,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}